Editact Therapeutics is thrilled to announce that its core technology has been awarded the prestigious Gold Medal at the International Exhibition of Inventions Geneva 2024. This esteemed recognition underscores the innovative advancements demonstrated by our research team, specifically designed to tackle the urgent medical challenges posed by Familial Alzheimer’s disease (FAD).

Our groundbreaking approach to brain-wide genome editing, which earned the Gold Medal, represents a significant leap forward in medical technology. By directly targeting the genetic cause, this revolutionary invention has the potential to alleviate the debilitating pathologies associated with FAD. We believe this technology could transform the landscape of treatment for familial diseases, offering hope to countless families affected by genetic conditions.

The International Exhibition of Inventions Geneva stands as one of the world’s largest and most prestigious annual events dedicated to innovation. This year, the exhibition featured an impressive 1,035 inventions from 38 countries and regions, and we are proud to be recognized among such esteemed company.